A case report and focused literature review of d‐penicillamine and severe neutropenia: A serious toxicity from a seldom‐used drug

Key Clinical Message Prescribing d‐penicillamine for Wilson's disease must be accompanied by vigilant monitoring, including a complete blood cell count with differential. For most, this should occur once or twice weekly during the first month of therapy and during periods of dose escalation, th...

Full description

Saved in:
Bibliographic Details
Published inClinical case reports Vol. 7; no. 5; pp. 990 - 994
Main Authors Pitman, Stuart K., Huynh, Tony, Bjarnason, Thorarinn A., An, Josiah, Malkhasyan, Karen A.
Format Journal Article
LanguageEnglish
Published England John Wiley & Sons, Inc 01.05.2019
John Wiley and Sons Inc
Subjects
Anemia
Antibiotics
Blood
Case Report
Case Reports
Copper
Drug dosages
Laboratories
Literature reviews
Neutropenia
Neutrophils
Patients
penicillamine
Revisions
Toxicity
Wilson's disease
United States > US
penicillamine
neutropenia
Wilson's disease
Online AccessGet full text

Cover

More Information
Summary:Key Clinical Message Prescribing d‐penicillamine for Wilson's disease must be accompanied by vigilant monitoring, including a complete blood cell count with differential. For most, this should occur once or twice weekly during the first month of therapy and during periods of dose escalation, then every two weeks for six additional months, then monthly. Prescribing d‐penicillamine for Wilson's disease must be accompanied by vigilant monitoring, including a complete blood cell count with differential. For most, this should occur once or twice weekly during the first month of therapy and during periods of dose escalation, then every two weeks for six additional months, then monthly.
ISSN:2050-0904
2050-0904
DOI:10.1002/ccr3.2125